Fort Washington Investment Advisors Inc. OH Acquires 63,769 Shares of Amgen Inc. (NASDAQ:AMGN)

Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3,222.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 65,748 shares of the medical research company’s stock after purchasing an additional 63,769 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Amgen were worth $20,543,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. International Assets Investment Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $32,880,000. GUNN & Co INVESTMENT MANAGEMENT INC. increased its stake in shares of Amgen by 1,089.5% in the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 108,838 shares of the medical research company’s stock valued at $31,348,000 after buying an additional 99,688 shares during the period. Silver Oak Securities Incorporated raised its position in shares of Amgen by 15.9% during the fourth quarter. Silver Oak Securities Incorporated now owns 1,366 shares of the medical research company’s stock worth $393,000 after acquiring an additional 187 shares during the last quarter. McAdam LLC acquired a new position in shares of Amgen during the fourth quarter valued at $208,000. Finally, Choreo LLC boosted its holdings in Amgen by 4.9% in the fourth quarter. Choreo LLC now owns 3,851 shares of the medical research company’s stock valued at $1,109,000 after acquiring an additional 180 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on AMGN shares. Oppenheimer restated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. Royal Bank of Canada raised their price objective on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 price target (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, Barclays raised Amgen from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Trading Up 0.9 %

AMGN opened at $333.83 on Friday. The firm’s fifty day simple moving average is $324.48 and its 200 day simple moving average is $300.43. The stock has a market capitalization of $179.08 billion, a P/E ratio of 47.69, a P/E/G ratio of 2.78 and a beta of 0.58. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 12 month low of $248.38 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same quarter in the previous year, the company posted $5.00 EPS. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, research analysts anticipate that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.70%. Amgen’s dividend payout ratio is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.